ライフサイエンスコーパス: corrected QT interval

1 raits (RR, P-wave, PR, and QRS intervals and corrected QT interval).

2 apeutics that can induce prolongation of the corrected QT interval.

3 dia, or apparent risk of prolongation of the corrected QT interval.

4 ngation of the action potential duration and corrected QT interval.

5 ormalities, particularly prolongation of the corrected QT interval.

6 T segment shift; and the duration of QRS and corrected QT intervals.

7 TS patients (84% male; age, 26 +/- 15 years; corrected QT interval, 329 +/- 22 ms) were studied, and

8 d adverse events were asymptomatic prolonged corrected QT interval (47%) and bradycardia (34%).

9 rmulas, only 24% to 32% of patients had rate-corrected QT intervals above 500 ms.

10 There was a small increase in corrected QT interval after ibutilide (from442 +/- 61 ms

11 Analysis of corrected QT interval among 74 control subjects from our

12 Prolongation of the corrected QT interval and elevation of liver-enzyme leve

13 ts (10 g of ethanol) per day with heart rate-corrected QT interval and heart rate assessed from elect

14 f this diagnosis even with a normal maternal corrected QT interval and lead to the initiation of spec

15 ing therapies may be effective in shortening corrected QT interval and reducing TdP recurrence risk.

16 Mechanisms for longer rate-corrected QT intervals and higher incidences of drug-ind

17 e variability were assessed every 30 min and corrected QT intervals and T-wave morphology every 60 mi

18 ventricular hypertrophy, prolongation of the corrected QT interval, and repolarization changes (ST/T

19 EMW outperformed heart rate-corrected QT interval as a predictor of symptomatic stat

20 urther, the majority of LQTS patients have a corrected QT interval below this threshold, and a signif

21 rolongation of either the QT interval or the corrected QT interval (calculated with Fridericia's form

22 ypes were neither associated with heart rate-corrected QT interval duration (QTc) nor cardiac events

23 were not associated with MeanNN, heart-rate-corrected QT interval duration (QTc), deceleration capac

24 gestive features that, along with heart rate-corrected QT interval duration, may risk stratify perina

25 The maximum corrected QT interval during treatment was significantly

26 Median corrected QT interval for heart rate was 312 ms (range:

27 in serum K(+) resulted in a decrease in the corrected QT interval from 526 +/- 94 to 423 +/- 36 ms (

28 A total of 1,059 LQTS patients with a corrected QT interval > or =450 ms presenting with synco

29 No patient in either group exhibited a corrected QT interval >/=500 msec.

30 A corrected QT interval >500 msecs was considered prolonge

31 pheral perfusion index without affecting the corrected QT interval, ICP, or HRV.

32 , fatigue in one; hypertension and prolonged corrected QT interval in another) occurred in patients i

33 +/-24.9) was longer than neonatal heart rate-corrected QT interval in both group 2 (491.2+/-27.6; P=0

34 ygotes, revealed an age-dependent heart rate-corrected QT interval increase (1% per additional 10 yea

35 Baseline corrected QT interval intervals did not differ between p

36 Variants investigated altered heart rate-corrected QT interval irrespective of mutation status, a

37 Prolonged heart rate-corrected QT interval is associated with higher risk of

38 lf is insufficient for diagnosis, unless the corrected QT interval is repeatedly >/=500 ms without an

39 ECG or arrhythmia phenotype, and only 2 had corrected QT interval longer than 500 milliseconds.

40 olic blood pressure, heart rate variability, corrected QT interval, low density lipoprotein (LDL) cho

41 probands displaying ST-segment elevation and corrected QT intervals < or = 360 ms had mutations in ge

42 me is a new clinical entity characterized by corrected QT intervals <300 ms and a high incidence of v

43 cantly (p < 0.05) prolonged, as indexed by a corrected QT interval (mean [+/-SD] 311 +/- 25 to 338 +/

44 -lumefantrine extended the electrocardiogram corrected QT interval (mean increase at 52 h compared wi

45 The neonatal heart rate-corrected QT interval (mean+/-SE) of group 1 (664.7+/-24

46 n-treatment electrocardiogram occurrences of corrected QT interval more than 500 ms (an indicator of

47 verage age of onset of 10 months, an average corrected QT interval of 676 ms, and a high prevalence o

48 After 72 hours, the corrected QT interval of the electrocardiogram was reduc

49 nicity index was increased (P<0.001) and the corrected QT interval on ECG was prolonged (P<0.001) in

50 d lansoprazole has been shown to prolong the corrected QT interval on electrocardiogram.

51 Prolonged heart rate-corrected QT interval on electrocardiograms (ECGs) is as

52 associated with uncorrected QT interval, HR-corrected QT interval or high-density lipoprotein-choles

53 RE: rs12734991 in meta-analysis: increase in corrected QT interval per C allele: 9.1 +/- 3.2 ms, p =

54 l fibrillation (9.4%), heart failure (8.6%), corrected QT interval prolongation (8.0%), and cardiac i

55 ated with a 23-fold increased odds of marked corrected QT interval prolongation (P=4x10(-25)), a mark

56 Corrected QT interval prolongation and tachyarrhythmias,

57 nation was not predicted by the magnitude of corrected QT interval prolongation but was associated wi

58 No significant associations were seen among corrected QT interval prolongation, repolarization chang

59 ed cardiac arrest, acute kidney failure, and corrected QT interval prolongation, were not significant

60 e groups, with the exception of asymptomatic corrected QT interval prolongation, which was significan

61 discontinuation of these medications due to corrected QT interval prolongation.

62 The proportion of patients who developed corrected QT-interval prolongation (p = 0.16), extrapyra

63 Arsenic is known to cause corrected QT-interval prolongation and T-wave changes, b

64 As expected, in TdP patients, many known corrected QT interval-prolonging risk factors were simul

65 a 7.7% +/- 0.9% shortening of the heart rate-corrected QT interval (QTc interval) in Kir2.1-transduce

66 All patients developed corrected QT interval (QTc interval) prolongation (media

67 ment depression (STD) >/=50 micro V and rate-corrected QT interval (QTc) >460 ms were examined as mea

68 ic testing correlated significantly with the corrected QT interval (QTc) and clinical diagnostic scor

69 to study the predictive value of heart rate-corrected QT interval (QTc) for incident coronary heart

70 Monitoring of the corrected QT interval (QTc) for patients with cancer rec

71 (P<0.05), and an increase in the heart rate-corrected QT interval (QTc) from 379+/-10 to 504+/-11 ms

72 Heart rate-corrected QT interval (QTc) is the traditional method of

73 Forty-five ECGs were available for corrected QT interval (QTc) measurement, and levels of h

74 arrhythmia, of which lengthening of the rate-corrected QT interval (QTc) on the electrocardiogram is

75 instigates an exploration into the causes of corrected QT interval (QTc) prolongation in these cases,

76 , 2 of 15 patients experienced dose-limiting corrected QT interval (QTc) prolongation, pneumonitis, o

77 Heart rate-corrected QT interval (QTc) prolongation, whether second

78 The corrected QT interval (QTc) should be assessed as a rout

79 n a recent cohort study, prolongation of the corrected QT interval (QTc) was associated with an indep

80 ded, manual measurements of QT intervals and corrected QT interval (QTc) were performed independently

81 forms in labeling prolongation of heart rate-corrected QT interval (QTc), an arrhythmia risk marker.

82 Piperaquine prolongs the corrected QT interval (QTc), and it is possible that rep

83 ying effects of AKAP9 variants on heart rate-corrected QT interval (QTc), cardiac events, and disease

84 gistic regression identified EMW, heart rate-corrected QT interval (QTc), female sex, and LQTS genoty

85 ration (PWD), PR interval, QRS duration, and corrected QT interval (QTc).

86 ) is characterized by a prolonged heart rate-corrected QT interval (QTc).

87 in cases with exertional syncope and normal corrected QT interval (QTc).

88 rrhythmia risk factors and quantification of corrected QT interval (QTc).

89 , and viruses such as SARS-CoV-2 may prolong corrected QT interval (QTc).

90 rate; systolic and diastolic blood pressure; corrected QT interval (QTc); sodium; potassium; aspartat

91 ects differed from control subjects: resting corrected QT interval (QTc, 627 +/- 90 versus 425 +/- 25

92 the risk for TdP included absolute and rate-corrected QT intervals (QTc) on drug therapy, the magnit

93 The median baseline corrected QT intervals (QTc) were 444 ms (gene negative)

94 ized into electrocardiographically affected (corrected QT interval [QTc] > or = 470 ms), borderline (

95 IQR], 7.7-23; range, 0-59, median heart rate-corrected QT interval [QTc] at diagnosis 557 ms (IQR, 52

96 dden cardiac death during childhood included corrected QT interval [QTc] duration > 500 ms (hazard ra

97 males, median age 16 years, average referral corrected QT interval [QTc] of 481 ms) referred with a d

98 G parameters (QRS voltage, QRS duration, and corrected QT interval [QTc]) were evaluated by using mul

99 tion potential and cause prolongation of the corrected QT interval, QTc.

100 ar-old female with an exaggerated heart rate-corrected QT interval response to metoclopramide ( QTc o

101 Longer corrected QT interval, substance abuse disorder, fluid a

102 alyses controlling for risk factors and rate-corrected QT interval, the PCA ratio remained a signific

103 One neonate had a grade 1 prolonged corrected QT interval using the Fridericia method that s

104 despite having essentially identical resting corrected QT interval values.

105 nd a significant minority has normal resting corrected QT interval values.

106 Mean corrected QT interval was 403 (standard deviation, 30) m

107 Maternal corrected QT interval was higher in those with pathogeni

108 Corrected QT interval was measured by surface ECG.

109 However, a prolonged rate-corrected QT interval was not a consistent feature, indi

110 The average corrected QT interval was significantly shorter in peopl

111 Frontal T axis, heart rate, and heart rate-corrected QT interval were the most significant ECG fact

112 In the 1270 (63%) with ECGs, corrected QT intervals were not different in variant car

113 duration of treatment, flecainide levels and corrected QT intervals were recorded; 24 h Holter monito

114 t alcohol units were not associated with the corrected QT interval, with beta = 1.04 (95% confidence